CD36 and diabetes mellitus: Using a combination of rodent, pig, and human tissues in combination with genetic and pharmacological in vivo and ex vivo approaches, we demonstrate increased CD36 S-acylation in diabetes, which is conserved between species and is sufficient to drive metabolic and contractile dysfunction.